Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population - Wikidata - wikimedia - TriplyDB

Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population

Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population

http://www.wikidata.org/entity/Q36464357

about

Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden.Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting.A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort.Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease.Breast cancer risk in rheumatoid arthritis: an update meta-analysis Comparison of cancer incidence among patients with rheumatic disease: a retrospective cohort study.Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study Autoimmune and Atopic Disorders and Risk of Classical Hodgkin Lymphoma Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis.The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.Differentially Methylated DNA Regions in Monozygotic Twin Pairs Discordant for Rheumatoid Arthritis: An Epigenome-Wide Study.Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-α inhibitor.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Adjuvants and lymphoma risk as part of the ASIA spectrum.How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries.No overall increased risk of cancer in patients with rheumatoid arthritis: a nationwide dynamic cohort study in Taiwan.Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.Association between autoimmune pancreatitis and malignancy.Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis.Coexistent malignant conditions in rheumatoid arthritis - A population-based cross-sectional study.Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.[Influence of therapy on risk of cancer in rheumatoid arthritis. Pathophysiological principles].Risk of virus-associated cancer in female arthritis patients treated with biological DMARDs-a cohort study.Chronic diseases, medical history and familial cancer, and risk of leukemia and non-Hodgkin's lymphoma in an adult population: a case-control study.[Lung cancer and rheumatoid arthritis. An interdisciplinary challenge].[Malignancies of the skin and immunomodulatory antirheumatic therapy].[Safe use of biological therapies for the treatment of rheumatoid arthritis and spondyloarthritides].What can rheumatologists learn from translational cancer therapy?Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.Should we be morbid about comorbidities in the rheumatic diseases?[Urological comorbidities in patients with rheumatoid arthritis : literature review].Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events.Sex, Symptom Severity, and Quality of Life in Rheumatology.[Lymphoma in rheumatic diseases].

P2860

Q26739361-51851462-B497-4659-AED6-159A8987F86F Q26799036-83DFB0B7-2ED0-4CB9-B659-011B1A52EDC4 Q28074148-AB0B0B57-09B9-401F-8B91-938DB265455C Q31041008-552A6710-86AA-4490-8F67-665E196AE82A Q33731716-9267FD3D-3454-4146-A66F-BE878BD4308B Q33734256-4F092DF4-1C29-4F15-919B-DADA0E548C4C Q33760824-B5CE294A-7C0D-459A-9C64-048385F9E7D3 Q34062402-02C56ECC-68A9-4ABD-9BCB-8A69B5B77B6F Q34487651-52FCBDEA-3618-4CF2-97DB-FCD3D56F1BEF Q34967765-564FBC42-1CE8-4403-9874-312DC8DA4D05 Q35605468-F3C46603-F25F-49C0-8B46-9F9E5868C1AE Q35813092-B98C633C-5381-4D68-ABA1-5DF6FA43F479 Q36089344-D58A808C-3C4D-432F-B948-3241325861BE Q36106183-8F9E81A0-DD15-46DE-A734-1D5727F8F56C Q37383424-F3B9E5D6-0432-4766-9A66-96ADA412D831 Q37418631-E6474C3C-37F9-4D8E-96BC-1BA1E217135E Q37616987-BE617FB3-4E45-42E4-98DB-94B1C9D9F5AE Q37656273-581D0FD1-B281-4D85-BFDE-D428708E0126 Q38176745-8EAB2461-F79B-4634-841F-AED300844175 Q38316047-EA98ADAC-DE36-45C3-8891-269B9718BFA9 Q38411038-CAE6D26C-1841-4944-A4DB-69E69E0BCC18 Q38421453-377072D9-792C-48D2-8067-7CB2C7D3F3F5 Q38642378-DE6B1077-A8E1-424B-8009-E7686C5B30A5 Q38983899-A5FCD79D-E1CA-4FC9-A1F0-B96B53EDB290 Q39309064-4B536DAB-FE7E-4EDC-9874-35D8FC6A9996 Q40354684-DDDBA4B9-7D8C-43AC-A572-2731054D1A3C Q40710011-9E4C23F5-B1EB-42F1-A43C-22D78D70BD5A Q40826525-8B8E183F-6586-4C60-9FCC-C65F3D79F3E0 Q40889610-4D3E1537-A135-4167-9845-A160835022EF Q40931527-991F3021-3F4A-464F-A973-92532757A725 Q40934508-848BB79A-902E-459E-B8D3-FBD3D813FA92 Q40949266-B737D0B9-5C1B-4D47-9987-B15918516025 Q41176187-92D1B13B-8D8E-4500-BC7C-C31281941D14 Q41535327-25EDC88D-E6E8-49AD-9728-206C94BAEBFA Q41605548-AEDC74F1-96C9-4787-9421-1DBABE9E98DE Q43854921-337712A2-CEF5-42A2-9817-82A334D774D6 Q44306281-FC4FBB47-426F-4670-BD09-E238423EA972 Q46339522-8F9639DE-F927-4FB4-95EE-FD678F5CE473 Q47671088-6EE530F7-75CD-4C59-BC57-06FBBDD79813 Q50057583-5517A895-BBCA-46FB-8068-C050ED502531

P2860

Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population

http://www.wikidata.org/entity/Q36464357

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Risk of cancer in patients rec ...... with the UK general population

@ast

Risk of cancer in patients rec ...... with the UK general population

@en

type

label

Risk of cancer in patients rec ...... with the UK general population

@ast

Risk of cancer in patients rec ...... with the UK general population

@en

prefLabel

Risk of cancer in patients rec ...... with the UK general population

@ast

Risk of cancer in patients rec ...... with the UK general population

@en

P1433

Q36464357-A0DFEB44-803D-4EB9-97FB-BAC3181686AA

P1476

Q36464357-90D16DBF-4429-4E23-B5E7-34BE358A859D

P2093

Q36464357-5B61D617-5E1B-47E9-98EB-9B4F615E8A07

Q36464357-91DDC0BA-6CDE-4746-9215-9FCD5B9B3FDA

Q36464357-C8853652-E66F-40D9-81D8-DB57A08FCC2C

Q36464357-E08FB32E-9A53-45FA-BB9B-912EFDE57090

Q36464357-E3B993C3-23D1-4A45-9E18-13C967FC61CE

Q36464357-EC73A044-336F-4361-BDD9-B073C7110F72

P2860

Q36464357-03622BDD-A5DC-4A91-B7F3-FC1E13C0C285

Q36464357-0AC6CD70-1F6E-4513-A2CB-703A8131A76E

Q36464357-13AC5505-BFA1-43DB-B212-6F8F613042AA

Q36464357-163B652E-C97B-4A19-9A4B-A80FBD5412EF

Q36464357-183AE017-1263-455E-93FF-66BDD07E365C

Q36464357-1B3E612A-5792-4E8E-8394-E517FDAD9BD3

Q36464357-2A8069C0-11F3-4F51-A460-3069DF838BC7

Q36464357-38FE5B73-415C-495E-B37A-03A6B6C8724C

Q36464357-4B175B58-5A80-4092-9599-887A9CCCCA96

Q36464357-4B903C61-711B-4FB8-897D-9888EE195C34

P304

Q36464357-BC98BFF1-15D1-4952-8C81-597CE307AD18

P31

Q36464357-B4C107B4-9AB4-46BF-BB25-9A8BB38C7B23

P356

Q36464357-51E9967C-A90A-41C4-A128-B08747A3FCBC

P433

Q36464357-6826DC9F-B2CE-4D1E-806C-60A260FDE0F9

P478

Q36464357-1B49FA3F-079A-41E2-B1F7-4C59A8F499F7

P50

Q36464357-796BFC4A-9A31-4824-B578-87DB1B207E5A

Q36464357-C72C18AB-98E1-410E-861D-641228F50553

Q36464357-DFC44EEF-BEB6-4841-8C9A-8963C1B28A42

Q36464357-F52F264E-A254-4990-8ECA-BBE044831748

P577

Q36464357-BB994EEC-0C41-48A5-A86E-20235700B879

P5875

Q36464357-6BEA0A70-375A-49AC-81C7-98CC954AE4C2

P698

Q36464357-9C37EED5-EF9F-4456-9BE9-0465DAD67633

P932

Q36464357-E943C48D-75F1-4B06-A29A-2CDC9D38A9E2

P356

P1433

P1476

Risk of cancer in patients rec ...... with the UK general population

@en

P2093

Audrey Low

http://www.w3.org/2001/XMLSchema#string

British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium

http://www.w3.org/2001/XMLSchema#string

Deborah P M Symmons

http://www.w3.org/2001/XMLSchema#string

Kath D Watson

http://www.w3.org/2001/XMLSchema#string

Kimme L Hyrich

http://www.w3.org/2001/XMLSchema#string

Louise K Mercer

http://www.w3.org/2001/XMLSchema#string

P2860

Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US

Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies

The incidence of bladder cancer after cyclophosphamide therapy

Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women's Health Study

Early inflammatory polyarthritis: results from the norfolk arthritis register with a review of the literature. I. Risk factors for the development of inflammatory polyarthritis and rheumatoid arthritis.

Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk

Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study.

Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens.

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

P304

91-98

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KES350

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

James B Galloway

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233914615

http://www.w3.org/2001/XMLSchema#string

P698

23238979

http://www.w3.org/2001/XMLSchema#string

P932

3521445

http://www.w3.org/2001/XMLSchema#string